These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 1717717)

  • 41. A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody.
    Warrier SV; Pinter A; Honnen WJ; Girard M; Muchmore E; Tilley SA
    J Virol; 1994 Jul; 68(7):4636-42. PubMed ID: 7515975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A predominant group-specific neutralizing epitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gp120.
    Berkower I; Murphy D; Smith CC; Smith GE
    J Virol; 1991 Nov; 65(11):5983-90. PubMed ID: 1717712
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
    Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
    Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
    J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.
    Hariharan K; Nara PL; Caralli VM; Norton FL; Haigwood N; Kang CY
    J Virol; 1993 Feb; 67(2):953-60. PubMed ID: 7678311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.
    Ren X; Sodroski J; Yang X
    J Virol; 2005 May; 79(9):5616-24. PubMed ID: 15827176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
    Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
    Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    Losman B; Bolmstedt A; Schønning K; Björndal A ; Westin C; Fenyö EM; Olofsson S
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1067-76. PubMed ID: 11485624
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
    Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
    J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence.
    Honnen WJ; Krachmarov C; Kayman SC; Gorny MK; Zolla-Pazner S; Pinter A
    J Virol; 2007 Feb; 81(3):1424-32. PubMed ID: 17121806
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of mutants of human immunodeficiency virus type 1 that have escaped neutralization by a monoclonal antibody to the gp120 V2 loop.
    Yoshiyama H; Mo H; Moore JP; Ho DD
    J Virol; 1994 Feb; 68(2):974-8. PubMed ID: 7507188
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.
    Poignard P; Fouts T; Naniche D; Moore JP; Sattentau QJ
    J Exp Med; 1996 Feb; 183(2):473-84. PubMed ID: 8627160
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.
    Mo H; Stamatatos L; Ip JE; Barbas CF; Parren PW; Burton DR; Moore JP; Ho DD
    J Virol; 1997 Sep; 71(9):6869-74. PubMed ID: 9261412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site.
    Cavacini LA; Emes CL; Power J; Buchbinder A; Zolla-Pazner S; Posner MR
    J Acquir Immune Defic Syndr (1988); 1993 Apr; 6(4):353-8. PubMed ID: 8455141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.
    Sanders RW; Venturi M; Schiffner L; Kalyanaraman R; Katinger H; Lloyd KO; Kwong PD; Moore JP
    J Virol; 2002 Jul; 76(14):7293-305. PubMed ID: 12072528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.